Catalog No.: PC-45871Not For Human Use, Lab Use Only.
CX-4945 sodium salt (Silmitasertib) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of protein kinase CK2 with Ki of 0.38 nM, CK2α IC50 of 1 nM.
CX-4945 sodium salt (Silmitasertib) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of protein kinase CK2 with Ki of 0.38 nM, CK2α IC50 of 1 nM.
CX-4945 sodium salt (Silmitasertib) displays good selectivity profile against a panel of 238 kinases.
CX-4945 sodium salt (Silmitasertib) attenuates PI3K/Akt signaling, blocks CK2-dependent HIF-1α transcription, caused cell cycle arrest and selectively induces apoptosis in cancer cells relative to normal cells.
CX-4945 sodium salt (Silmitasertib) exhibits antitumor efficacy in murine xenograft models.
Physicochemical Properties
M.Wt
371.7523
Formula
C19H11ClN3NaO2
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
Benzo[c]-2,6-naphthyridine-8-carboxylic acid, 5-[(3-chlorophenyl)amino]-, sodium salt (1:1)
References
1. Pierre F, et al. J Med Chem. 2011 Jan 27;54(2):635-54.
2. Siddiqui-Jain A, et al. Cancer Res. 2010 Dec 15;70(24):10288-98.
3. Siddiqui-Jain A, et al. Mol Cancer Ther. 2012 Apr;11(4):994-1005.
